newsfilter
← Latest News
GlobeNewswire·

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701